Mallinckrodt PLC (NYSE:MNK) CEO Mark Trudeau bought 5,000 shares of Mallinckrodt PLC stock in a transaction on Friday, November 10th. The stock was purchased at an average price of $22.28 per share, with a total value of $111,400.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Mallinckrodt PLC (NYSE:MNK) opened at $21.90 on Tuesday. The company has a quick ratio of 1.05, a current ratio of 1.38 and a debt-to-equity ratio of 1.08. Mallinckrodt PLC has a twelve month low of $19.00 and a twelve month high of $68.12. The stock has a market capitalization of $2,067.31, a P/E ratio of 2.94, a PEG ratio of 0.33 and a beta of 1.46.
Mallinckrodt PLC (NYSE:MNK) last issued its quarterly earnings data on Tuesday, November 7th. The company reported $1.97 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.17. Mallinckrodt PLC had a return on equity of 14.79% and a net margin of 11.43%. The business had revenue of $793.90 million for the quarter, compared to the consensus estimate of $808.93 million. During the same period in the prior year, the business earned $2.04 earnings per share. The business’s revenue was down 10.5% on a year-over-year basis. sell-side analysts forecast that Mallinckrodt PLC will post 7.23 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://transcriptdaily.com/2017/11/14/mallinckrodt-plc-mnk-ceo-mark-trudeau-purchases-5000-shares-of-stock.html.
Several equities research analysts have commented on the company. BidaskClub lowered Mallinckrodt PLC from a “sell” rating to a “strong sell” rating in a research report on Friday, August 18th. Canaccord Genuity lowered their price objective on Mallinckrodt PLC from $38.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, November 8th. UBS AG lowered Mallinckrodt PLC from a “buy” rating to a “neutral” rating and set a $24.00 target price on the stock. in a research report on Monday. Barclays PLC lowered Mallinckrodt PLC from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $65.00 to $23.00 in a research report on Wednesday, November 8th. Finally, Oppenheimer Holdings, Inc. set a $70.00 target price on Mallinckrodt PLC and gave the company a “buy” rating in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $48.14.
Large investors have recently modified their holdings of the company. Denali Advisors LLC purchased a new stake in shares of Mallinckrodt PLC in the second quarter valued at $112,000. Sterling Capital Management LLC acquired a new position in Mallinckrodt PLC in the second quarter valued at $204,000. Advisor Partners LLC acquired a new position in Mallinckrodt PLC in the second quarter valued at $242,000. Municipal Employees Retirement System of Michigan increased its stake in Mallinckrodt PLC by 24.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 5,640 shares of the company’s stock valued at $253,000 after purchasing an additional 1,110 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new position in Mallinckrodt PLC in the second quarter valued at $260,000. Institutional investors and hedge funds own 98.83% of the company’s stock.
About Mallinckrodt PLC
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.